...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Relationship between Body Mass Index and Anti-Hypertensive Efficacy of Doxazosin According to a Survey of Japanese Patients
【24h】

Relationship between Body Mass Index and Anti-Hypertensive Efficacy of Doxazosin According to a Survey of Japanese Patients

机译：根据日本患者的调查，体重指数与多沙唑嗪的抗高血压功效之间的关系

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this cross-sectional study, we surveyed a population of 101 hypertensive patients in Japan to determine the efficacy of the blood pressure lowering effect of α1-blockers in relation to their body mass index (BMI). We found that doxazosin was frequently administered to obese hypertensive patients; many patients treated with doxazosin were taking concomitant medication. We also demonstrated that the higher the dose of doxazosin, the lower the ambulatory blood pressure measured in the out-patient clinic. Doxazosin showed a more favourable blood pressure lowering effect in patients with a higher BMI. These results suggest that anti-hypertensive drugs are useful when used in obese patients receiving multiple concomitant medications. These patients would normally be considered to show a poor response to anti-hypertensive treatment. Furthermore, we expect the α1-blocker doxazosin to demonstrate a dose-dependent effect in obese patients with hypertension.
机译：在这项横断面研究中，我们调查了日本的101名高血压患者，以确定相对于其体重指数（BMI）的α1-受体阻滞剂降压效果。我们发现多沙唑嗪经常用于肥胖的高血压患者。多沙唑嗪治疗的许多患者都在服用药物。我们还证明了多沙唑嗪的剂量越高，门诊诊所测量的门诊血压越低。多沙唑嗪在BMI较高的患者中显示出更有利的降血压作用。这些结果表明，在接受多种同时用药的肥胖患者中使用降压药是有用的。通常认为这些患者对抗高血压治疗反应较差。此外，我们期望α1受体阻滞剂多沙唑嗪在肥胖的高血压患者中表现出剂量依赖性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号